BioCentury

12:38 AM GMT, Oct 6, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

XenoPort up on Phase I data for potential autoimmune therapy

XenoPort Inc. (NASDAQ:XNPT) gained $1.71 (15%) to $12.86 on Friday after reporting

Read the full 127 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.